Literature DB >> 2550788

Binding of nuclear factor EF-C to a functional domain of the hepatitis B virus enhancer region.

P Ostapchuk1, G Scheirle, P Hearing.   

Abstract

Nuclear factor EF-C is present in extracts prepared from human HepG2 liver cells and from other, nonliver cell lines and binds to the hepatitis B virus and polyomavirus transcriptional enhancer regions in vitro. An inverted repeat (5'-GTTGCNNNGCAAC-3') is located within both binding regions. Diethyl pyrocarbonate interference binding assays and competition binding experiments using altered binding sites demonstrated that EF-C contacts symmetrical nucleotides within the inverted repeat. Mutations that changed the length of the spacer region between the arms of the inverted repeat were introduced in the hepatitis enhancer region. Introduction of 1 or 2 base pairs between the repeats did not affect EF-C binding, but deletion of 1 base pair or introduction of 3 to 9 base pairs reduced binding dramatically. Introduction of 10 base pairs restored partial EF-C binding ability. These and other results suggest that EF-C binding is stabilized by dimerization. In vivo assays for enhancer function using these mutants demonstrated that the EF-C binding site is a functional and important component of the hepatitis B virus enhancer region.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550788      PMCID: PMC362744          DOI: 10.1128/mcb.9.7.2787-2797.1989

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  55 in total

1.  The thyroid hormone receptor binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements.

Authors:  C K Glass; J M Holloway; O V Devary; M G Rosenfeld
Journal:  Cell       Date:  1988-07-29       Impact factor: 41.582

2.  Transcription of hepatitis B virus by RNA polymerase II.

Authors:  L B Rall; D N Standring; O Laub; W J Rutter
Journal:  Mol Cell Biol       Date:  1983-10       Impact factor: 4.272

3.  Nucleotide sequence of an infectious molecularly cloned genome of ground squirrel hepatitis virus.

Authors:  C Seeger; D Ganem; H E Varmus
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

4.  Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences.

Authors:  E Mandart; A Kay; F Galibert
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

5.  Evidence of extrachromosomal forms of hepatitis B viral DNA in a bone marrow culture obtained from a patient recently infected with hepatitis B virus.

Authors:  E Elfassi; J L Romet-Lemonne; M Essex; M Frances-McLane; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

6.  The cloned genome of ground squirrel hepatitis virus is infectious in the animal.

Authors:  C Seeger; D Ganem; H E Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

7.  Signals regulating hepatitis B surface antigen transcription.

Authors:  R Cattaneo; H Will; N Hernandez; H Schaller
Journal:  Nature       Date:  1983 Sep 22-28       Impact factor: 49.962

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Hepatitis B virus infection in cultured human lymphoblastoid cells.

Authors:  J L Romet-Lemonne; M F McLane; E Elfassi; W A Haseltine; J Azocar; M Essex
Journal:  Science       Date:  1983-08-12       Impact factor: 47.728

10.  Hepatitis B virus transcription in the infected liver.

Authors:  R Cattaneo; H Will; H Schaller
Journal:  EMBO J       Date:  1984-09       Impact factor: 11.598

View more
  28 in total

1.  Mutational analysis of enhancer domains responsive to trans-activation by the X gene of human hepatitis B virus.

Authors:  G Goodarzi; H Ohno; R Adams; A Darabi; A Tewari; M Watabe; K Watabe
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

2.  Characterization of the hepatitis B virus EnhI enhancer and X promoter complex.

Authors:  W T Guo; K D Bell; J H Ou
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

3.  Compilation of vertebrate-encoded transcription factors.

Authors:  S Faisst; S Meyer
Journal:  Nucleic Acids Res       Date:  1992-01-11       Impact factor: 16.971

4.  p140/c-Abl that binds DNA is preferentially phosphorylated at tyrosine residues.

Authors:  R Dikstein; R Agami; D Heffetz; Y Shaul
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

5.  Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II.

Authors:  K Ueda; Y Wei; D Ganem
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Interactions of the transcription factors MIBP1 and RFX1 with the EP element of the hepatitis B virus enhancer.

Authors:  M Blake; J Niklinski; M Zajac-Kaye
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

7.  The transcriptional activation and repression domains of RFX1, a context-dependent regulator, can mutually neutralize their activities.

Authors:  Y Katan; R Agami; Y Shaul
Journal:  Nucleic Acids Res       Date:  1997-09-15       Impact factor: 16.971

8.  Functional organization of the hepatitis B virus enhancer.

Authors:  R Dikstein; O Faktor; R Ben-Levy; Y Shaul
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

9.  Induction of Myc-intron-binding polypeptides MIBP1 and RFX1 during retinoic acid-mediated differentiation of haemopoietic cells.

Authors:  M Zajac-Kaye; N Ben-Baruch; E Kastanos; F J Kaye; C Allegra
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

10.  Transcription factors RFX1/EF-C and ATF-1 associate with the adenovirus E1A-responsive element of the human proliferating cell nuclear antigen promoter.

Authors:  C Labrie; B H Lee; M B Mathews
Journal:  Nucleic Acids Res       Date:  1995-09-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.